BlossomHill Therapeutics, Inc.
Blossomhill Therapeutics, Inc. is a biopharmaceutical company. It engages in the development of small molecule medicines for unmet medical needs in cancer treatment. The company was founded in June 2020 and is headquartered in San Diego, CA.
1D
-6.9%
1W
-20.3%
1M
-46.9%
6M
–
YTD
–
1Y
–
2Y
–
5Y
–
10Y
–
Next earnings date
18/12/2026 (in 62 days)
Volatility around earnings
Not enough history for an assessment
PRICE TARGET LOW
US$35.00
CONSENSUS
US$38.33
MEDIAN
US$40.00
PRICE TARGET HIGH
US$40.00
0
STRONG BUY
2
BUY
0
HOLD
0
SELL
0
STRONG SELL
2
TOTAL · Buy
As of: 21/09/2026
P/E
-1.47
P/B
4.61
EV/EBITDA
-7.15
RETURN ON EQUITY
-29.0%
NET MARGIN
0.0%
DEBT/EQUITY
0.28
DIVIDEND YIELD
0.0%
AS OF
30/06/2026
FREE FLOAT
77.7%
FLOAT SHARES
22,588,994
AVG. DAILY VOLUME (30D)
222,059
ORBIMED ADVISORS LLC
ORBIMED ADVISORS LLC
ORBIMED ADVISORS LLC
GORDON CARL L
GORDON CARL L
BlossomHill Therapeutics, Inc. is a company in the Healthcare sector, Biotechnology industry, headquartered in United States.
The CEO is Jing Rong Jean Cui, the company employs around 69 people.
The IPO was on 07/08/2026; the stock trades on NASDAQ under the ticker BLSM.
2 analysts rate the stock, the consensus is Buy (as of 21/09/2026).
The average price target is US$38.33, ranging from US$35.00 to US$40.00, with a median of US$40.00.
This is an external assessment, not a statement by Market Jury.
The next earnings date is 18/12/2026.
No, BlossomHill Therapeutics currently does not pay a dividend.
Comparable stocks include Vertex Pharmaceuticals, Moderna, Regeneron Pharmaceuticals, Revolution Medicines, Incyte, Exelixis, Neurocrine Biosciences and Summit Therapeutics.
Clicking "Analyze stock" lets five strategies assess BlossomHill Therapeutics against fixed, published rules and judge it bullish, neutral or bearish. The jury states where it disagrees. A free account starts with 5 credits, a quick check costs 1 credit, a full analysis 2 credits.
Not investment advice. Past performance is not an indicator of future results.